Tango Therapeutics

TNGX

Market cap $3.57B

-  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  -

27,000 common shares were sold via option exercise on April 1, 2026, generating proceeds of approximately $572,000 at a weighted average of $21.20 per share. The transaction reduced Adam's direct common stock position from 139,622 to 112,622 shares -- a reduction of 19.34% of her pre-sale holdings.

Adam Crystal sold 20,251 shares for a transaction value of ~$304,000 on March 5, 2026, at an average price of around $15 per share. This sale represented 15.24% of Crystal's direct holdings, reducing his directly held position from 132,873 to 112,622 shares.

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.

Tango Therapeutics, Inc. is downgraded to Hold after a sharp rally, with 2026 positioned as a pivotal, data-driven year. Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a $343m cash position, partnerships with Gilead and Revolution Medicines, and multiple upcoming data catalysts, but faces fierce competition.

Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca.

Purchased 1,104,734 shares of Tango Therapeutics; estimated trade size $9.52 million based on quarterly average pricing Quarter-end position value increased by $14.28 million, reflecting both trading and stock price changes Added stake equivalent to 2.08% of 13F reportable assets under management (AUM) Post-trade, fund holds 10,876,219 shares valued at $96.36 million Position now represents 21.09% of fund AUM, which makes it the fund's n/a largest holding

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience and who has served on the Tango Board of Directors since 2018, who will drive the next phase of company growth.